The facility is located at Texas A&M Health Science Center's Institute for Biotechnology. The core screening facility is directed by Dr. Peter Davies and Dr. Cliff Stephan.
Details
The core screening facility for the GCC for Chemical Genomics allows for high-throughput screening (including assay development, primary screens, preliminary data analysis, target identification, concentration-response, and secondary screens) using the following available compound collections: Custom Clinical Collection – 145 FDA approved (Clinical candidates in cancer); EMD/Calbiochem – 224 Kinase inhibitors; NIH Clinical Collection – 471 former clinical candidates; Prestwick (2012) – 2000 Off-patent drugs, bioactive compounds; Microsource (2009) – 2000 Off-patent drugs, NP, killers; Medina (2011) – 2500 Fungal extract peak fractions; NCI (2012) – 2872 Diversity set, Mechanistic set, NP, Oncology set; Maybridge Hitfinder (2009) – 14,400 small molecules; Chembridge DIVERSet – 30,080 small molecules.
Important Disclaimer: The responsibility for the accuracy of the information contained on these pages lies with the authors and user providing such information.